SAB Biotherapeutics Inc

Change company Symbol lookup

Select an option...

SABS SAB Biotherapeutics Inc

DIA SPDR® Dow Jones Industrial Average ETF Trust

SPY SPDR® S&P 500 ETF Trust

ABBNY Abb Ltd

FCF First Commonwealth Financial Corp

ARMN Aris Mining Corp

IBM International Business Machines Corp

JPM JPMorgan Chase & Co

GEHC GE Healthcare Technologies Inc

GE General Electric Co

Go

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Its DiversitAb platform is applicable to a range of serious unmet needs in human diseases. It produces fully human polyclonal immunotherapies without the need for human donors. Its product candidates include SAB-185, a fully human polyclonal antibody therapeutic for the treatment of coronavirus disease, and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. Its preclinical stage assets SAB-195 is the first-in-class fully human hIgG treatment for the treatment of Clostridioides difficile infection (CDI), and SAB-142 is a multi-indication potential asset developed for organ transplant induction and organ transplant rejection, among other immunological indications.